138 related articles for article (PubMed ID: 24325696)
1. Commentary: how do we deal with dissection after angioplasty?
Fanelli F; Cannavale A; Gazzetti M; D'Adamo A
J Endovasc Ther; 2013 Dec; 20(6):801-4. PubMed ID: 24325696
[No Abstract] [Full Text] [Related]
2. Commentary: treatment of femoropopliteal in-stent restenosis for patients with diabetes: do we have an answer to the DEBATE?
Armstrong EJ; Laird JR
J Endovasc Ther; 2014 Feb; 21(1):9-11. PubMed ID: 24502478
[No Abstract] [Full Text] [Related]
3. Percutaneous revascularization for peripheral arterial disease: paclitaxel saves the day.
Mahmud E
JACC Cardiovasc Interv; 2013 Mar; 6(3):290-2. PubMed ID: 23517841
[No Abstract] [Full Text] [Related]
4. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study.
Tepe G; Zeller T; Schnorr B; Claussen CD; Beschorner U; Brechtel K; Scheller B; Speck U
J Endovasc Ther; 2013 Dec; 20(6):792-800. PubMed ID: 24325695
[TBL] [Abstract][Full Text] [Related]
5. The THUNDER trial results: clearing the way or ushering the storm?
Jaff MR
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):109-10. PubMed ID: 25616823
[No Abstract] [Full Text] [Related]
6. Commentary: aligning incentives of payer, facility, and provider: the lynchpin of providing more cost-effective care.
Sternbergh WC
J Endovasc Ther; 2013 Dec; 20(6):826-7. PubMed ID: 24325700
[No Abstract] [Full Text] [Related]
7. Commentary: comparative effectiveness of paclitaxel-based femoropopliteal interventions.
Armstrong EJ
J Endovasc Ther; 2014 Jun; 21(3):369-72. PubMed ID: 24915583
[No Abstract] [Full Text] [Related]
8. Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoropopliteal Occlusive Disease: The BIOPAC Trial.
Buszman PP; Nowakowski P; Milewski K; Orlik B; Żurakowski A; Ludyga T; Polczyk F; Dębiński M; Jelonek M; Kachel M; Gąsior M; Granada JF; Kiesz RS; Buszman PE
JACC Cardiovasc Interv; 2018 Dec; 11(23):2436-2438. PubMed ID: 30522679
[No Abstract] [Full Text] [Related]
9. Drug-coated balloons--the importance of packing and dosing antiproliferative drugs.
Hehrlein C
Catheter Cardiovasc Interv; 2015 Aug; 86(2):287-8. PubMed ID: 26198065
[TBL] [Abstract][Full Text] [Related]
10. Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain.
Zeller T; Brodmann M; Micari A; Keirse K; Peeters P; Tepe G; Scheinert D; Jaff MR; Rocha-Singh KJ; Li P; Schmahl R; Ansel GM;
Circ Cardiovasc Interv; 2019 Jan; 12(1):e007730. PubMed ID: 30630355
[No Abstract] [Full Text] [Related]
11. David versus Goliath: the first round.
Micari A; Vadalà G
JACC Cardiovasc Interv; 2014 Sep; 7(9):1057-9. PubMed ID: 25234680
[No Abstract] [Full Text] [Related]
12. How should I treat a restenosis after superficial femoral artery stenting?
Fusaro M; Cassese S; Byrne RA
EuroIntervention; 2013 Mar; 8(11):1342-5. PubMed ID: 23538161
[No Abstract] [Full Text] [Related]
13. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
14. Missing the Forest for the Trees?: Drug-Eluting Balloon Treatment for Infrapopliteal Disease.
Tsai TT
JACC Cardiovasc Interv; 2015 Oct; 8(12):1623-5. PubMed ID: 26493254
[No Abstract] [Full Text] [Related]
15. Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative.
Bertges DJ; Sedrakyan A; Sun T; Eslami MH; Schermerhorn M; Goodney PP; Beck AW; Cronenwett JL; Eldrup-Jorgensen J
Circ Cardiovasc Interv; 2020 Feb; 13(2):e008528. PubMed ID: 32069110
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Mortality Following Paclitaxel Drug-Coated Balloon Angioplasty of Femoropopliteal Lesions in the Real World.
Böhme T; Noory E; Beschorner U; Jacques B; Bürgelin K; Macharzina R; Gebauer E; Cheung F; Lechner P; Nührenberg T; Zeller T
JACC Cardiovasc Interv; 2020 Sep; 13(17):2052-2061. PubMed ID: 32593696
[TBL] [Abstract][Full Text] [Related]
17. Comparison of paclitaxel-coated balloon angioplasty with femoropopliteal bypass surgery in treating femoropopliteal lesions.
Kavala AA; Kuserli Y; Turkyilmaz S
Vascular; 2021 Apr; 29(2):260-269. PubMed ID: 32838692
[TBL] [Abstract][Full Text] [Related]
18. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
Fanelli F; Cannavale A; Citone M; Santoni M; Gazzetti M; Falcone GM; Miele V
J Endovasc Ther; 2020 Feb; 27(1):34-41. PubMed ID: 31637956
[No Abstract] [Full Text] [Related]
19. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
[No Abstract] [Full Text] [Related]
20. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
Scheinert D; Duda S; Zeller T; Krankenberg H; Ricke J; Bosiers M; Tepe G; Naisbitt S; Rosenfield K
JACC Cardiovasc Interv; 2014 Jan; 7(1):10-9. PubMed ID: 24456716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]